Efficiency of recombinant human TNFin human cancer therapy

Cancer immunity

,²  Curzio Rüegg¹  Danielle Liénard¹  Maurice Matter³  FerdyJ. Lejeune¹ 

[1] Multidisciplinary Oncology Centre (CePO), Lausanne, SwitzerlandMultidisciplinary Oncology Centre (CePO), Lausanne, SwitzerlandMultidisciplinary Oncology Centre (CePO), Lausanne, Switzerland;Ludwig Institute for Cancer Research(LICR), Lausanne Branch, Lausanne, SwitzerlandLudwig Institute for Cancer Research(LICR), Lausanne Branch, Lausanne, SwitzerlandLudwig Institute for Cancer Research(LICR), Lausanne Branch, Lausanne, Switzerland;Department of Visceral Surgery, CentreHospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDepartment of Visceral Surgery, CentreHospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDepartment of Visceral Surgery, CentreHospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

关键词: human;    neoplasms;    TNF;    melphalan;    isolated limb perfusion;    survival rate;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown